Literature DB >> 17199018

Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain.

Alan B Ettinger1, Charles E Argoff.   

Abstract

Antiepileptic drugs (AEDs) are commonly utilized for nonepileptic conditions, including various psychiatric disorders and pain syndromes. Evidence for their benefit in these nonepileptic conditions varies widely among different drugs, but there is, in general, a paucity of published multicenter randomized double-blind trials. Variable levels of evidence suggest that lamotrigine and the vagal nerve stimulator have antidepressant properties. Carbamazepine, valproate, lamotrigine, and oxcarbazepine appear to have mood stabilizing properties while gabapentin, pregabalin, and tiagabine have anxiolytic benefits. Barbiturates, topiramate, and possibly phenytoin may precipitate or exacerbate depression. Underlying depression and anxiety symptoms may be exacerbated by levetiracetam, while psychotic symptoms have rarely been reported with topiramate, levetiracetam, and zonisamide. Pregabalin, gabapentin, carbamazepine, and oxcarbazepine have been used to treat neuropathic pain such as postherpetic neuralgia, and diabetic polyneuropathy. Topiramate and divalproex sodium have utility in the prophylaxis or acute treatment of migraine. Further rigorous studies are needed to clarify the utility of AEDs in nonepileptic conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17199018     DOI: 10.1016/j.nurt.2006.10.003

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  117 in total

Review 1.  Antiepileptic drugs in mood-disordered patients.

Authors:  Prashant Gajwani; Anna Forsthoff; David Muzina; Benedikt Amann; Keming Gao; Omar Elhaj; Joseph R Calabrese; Heinz Grunze
Journal:  Epilepsia       Date:  2005       Impact factor: 5.864

Review 2.  Topiramate for acute affective episodes in bipolar disorder.

Authors:  Kamini Vasudev; Karine Macritchie; John Geddes; Stuart Watson; Allan Young
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

3.  Placebo-controlled study of divalproex sodium for agitation in dementia.

Authors:  A P Porsteinsson; P N Tariot; R Erb; C Cox; E Smith; L Jakimovich; J Noviasky; N Kowalski; C J Holt; C Irvine
Journal:  Am J Geriatr Psychiatry       Date:  2001       Impact factor: 4.105

4.  Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study.

Authors:  Marius K Nickel; Cerstin Nickel; Patrick Kaplan; Claas Lahmann; Moritz Mühlbacher; Karin Tritt; Jakub Krawczyk; Peter K Leiberich; Wolfhardt K Rother; Thomas H Loew
Journal:  Biol Psychiatry       Date:  2005-03-01       Impact factor: 13.382

5.  A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal.

Authors:  John J Mariani; Richard N Rosenthal; Susan Tross; Prameet Singh; Om P Anand
Journal:  Am J Addict       Date:  2006 Jan-Feb

6.  Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

Authors:  Marius K Nickel; Cerstin Nickel; Ferdinand O Mitterlehner; Karin Tritt; Claas Lahmann; Peter K Leiberich; Wolfhardt K Rother; Thomas H Loew
Journal:  J Clin Psychiatry       Date:  2004-11       Impact factor: 4.384

7.  Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats.

Authors:  E Southam; D Kirkby; G A Higgins; R M Hagan
Journal:  Eur J Pharmacol       Date:  1998-09-25       Impact factor: 4.432

8.  An open-label study of levetiracetam for the treatment of social anxiety disorder.

Authors:  Naomi M Simon; John J Worthington; Alicia C Doyle; Elizabeth A Hoge; Gustavo Kinrys; Diana Fischmann; Nathaniel Link; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2004-09       Impact factor: 4.384

9.  Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate.

Authors:  Ninan T Mathew; Jayasree Kailasam; Lori Meadors
Journal:  Headache       Date:  2002-09       Impact factor: 5.887

10.  Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder.

Authors:  Jeffrey L Berlant
Journal:  BMC Psychiatry       Date:  2004-08-18       Impact factor: 3.630

View more
  24 in total

1.  Stability of Extemporaneously Compounded Levetiracetam in Glass and Plastic Bottles and Plastic Syringes.

Authors:  Mary H H Ensom; Diane Décarie
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

2.  Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

Authors:  David F McComsey; Virginia L Smith-Swintosky; Michael H Parker; Douglas E Brenneman; Ewa Malatynska; H Steve White; Brian D Klein; Karen S Wilcox; Michael E Milewski; Mark Herb; Michael F A Finley; Yi Liu; Mary Lou Lubin; Ning Qin; Allen B Reitz; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2013-11-11       Impact factor: 7.446

3.  Stability of levetiracetam in extemporaneously compounded suspensions.

Authors:  Mary H H Ensom; Diane Decarie; Susan Rudolph
Journal:  Can J Hosp Pharm       Date:  2011-05

4.  Mood Spectrum Disorders and Perception of Pain.

Authors:  Antonella Ciaramella
Journal:  Psychiatr Q       Date:  2017-12

5.  Nociceptive blink reflex habituation biofeedback in migraine.

Authors:  M de Tommaso; M Delussi
Journal:  Funct Neurol       Date:  2017 Jul/Sep

6.  Psychosomatic factors in pruritus.

Authors:  Hong Liang Tey; Joanna Wallengren; Gil Yosipovitch
Journal:  Clin Dermatol       Date:  2013 Jan-Feb       Impact factor: 3.541

7.  Forecasting drug utilization and expenditure in a metropolitan health region.

Authors:  Björn Wettermark; Marie E Persson; Nils Wilking; Mats Kalin; Seher Korkmaz; Paul Hjemdahl; Brian Godman; Max Petzold; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-05-17       Impact factor: 2.655

Review 8.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Acute antiepileptic drug use in intensive care units.

Authors:  Bernd J Vorderwülbecke; Gregor Lichtner; Falk von Dincklage; Martin Holtkamp
Journal:  J Neurol       Date:  2018-09-26       Impact factor: 4.849

10.  Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system.

Authors:  Anne C VanCott; Joyce A Cramer; Laurel A Copeland; John E Zeber; Michael A Steinman; Jeffrey J Dersh; Mark E Glickman; Eric M Mortensen; Megan E Amuan; Mary Jo Pugh
Journal:  BMC Med       Date:  2010-01-11       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.